🇺🇸 Nitroprusside, Sodium in United States

36 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 36

Most-reported reactions

1. Cardiac Failure — 6 reports (16.67%)
2. Fatigue — 4 reports (11.11%)
3. Product Name Confusion — 4 reports (11.11%)
4. Respiratory Failure — 4 reports (11.11%)
5. Depression — 3 reports (8.33%)
6. Diarrhoea — 3 reports (8.33%)
7. Fall — 3 reports (8.33%)
8. Loss Of Consciousness — 3 reports (8.33%)
9. Pain — 3 reports (8.33%)
10. Pneumonia — 3 reports (8.33%)

Source database →

Frequently asked questions

Is Nitroprusside, Sodium approved in United States?

Nitroprusside, Sodium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Nitroprusside, Sodium in United States?

Cristália Produtos Químicos Farmacêuticos Ltda. is the originator. The local marketing authorisation holder may differ — check the official source linked above.